What is Beta Bionics?
Headquartered in Massachusetts and California, Beta Bionics operates as a public benefit corporation and Certified B Corporation dedicated to the development of the iLet Bionic Pancreas System. The platform integrates continuous glucose monitoring with autonomous insulin and glucagon administration to mimic natural physiological responses. By focusing on glycemic dysregulation, the company occupies a pivotal position in the digital health landscape, bridging the gap between complex medical technology and patient-centric care. Its commitment to clinical-stage innovation has established it as a key player in the evolution of automated diabetes management.
How much funding has Beta Bionics raised?
Beta Bionics has raised a total of $495.6M across 7 funding rounds:
Angel/Seed
$1M
Private Equity
$2.5M
Series B
$63M
Series C
$57M
Series D
$100M
Series E
$60M
Stock Offering
$212.1M
Angel/Seed (2016): $1M, investors not publicly disclosed
Private Equity (2017): $2.5M, investors not publicly disclosed
Series B (2019): $63M supported by Zealand Pharma A/S, RTW Investments, LifeSci Venture Partners, ArrowMark Partners, and Dexcom
Series C (2022): $57M featuring Pura Vida Investments, RTW Investments, Farallon, Perceptive Advisors, Eventide Asset Management, Novo Nordisk, LifeSci Venture Partners, Soleus Capital, and ArrowMark Partners
Series D (2023): $100M backed by OMEGA Funds Investment, Sands Capital, and Marshall Wace
Series E (2024): $60M with participation from Wellington Management and Eventide Asset Management
Stock Issuance/Offering (2025): $212.1M, investors not publicly disclosed
Key Investors in Beta Bionics
RTW Investments
A life sciences investment firm that focuses on biotech and medtech innovation throughout the entire lifecycle, providing both capital and deep scientific expertise.
Eventide Asset Management
An investment firm that emphasizes a values-based approach, focusing on healthcare and technology sectors to create positive impact alongside financial returns.
LifeSci Venture Partners
A venture firm specializing in molecular medicine and technology, providing comprehensive support to emerging biopharma companies transitioning to public markets.
What's next for Beta Bionics?
With the recent influx of capital, Beta Bionics is well-positioned to accelerate the commercialization of its core technology. The strategic focus will likely shift toward expanding market access and refining the iLet system's algorithmic capabilities to improve health outcomes for a broader patient demographic. As the company matures, the emphasis will remain on maintaining its rigorous clinical standards while scaling its infrastructure to meet the global demand for advanced, autonomous medical devices. Future milestones will likely involve deeper integration with existing healthcare ecosystems and the pursuit of long-term sustainability in the competitive medtech market.
See full Beta Bionics company page
